Graph AI Secures $13.3 Million to Revolutionize Drug Safety with AI
Graph AI has raised $13.3 million in a Series A round led by Insight Partners.
Bessemer Venture Partners also joined the round to support the company's growth.
AI Transforms Patient Safety Workflows
The funding will help expand operations across the US and Europe.
Graph AI develops the Graph Safety platform for pharmacovigilance tasks.
Its technology automates the handling of adverse event reports from drugs.
In real deployments the system cuts case processing time from over three hours to under 10 minutes.
Operating costs have dropped by up to 66 percent according to company data.
Broader Impact on Global Health and Pharma Innovation
Founded in 2024 the startup targets inefficiencies in traditional drug safety monitoring.
This approach could lead to faster identification of medicine risks for patients worldwide.
By reducing manual work safety teams can focus more on complex decisions and analysis.
The platform supports regulatory compliance with built-in audit trails and human oversight.
Future modules will enhance reporting and signal detection for emerging safety issues.
Overall this investment highlights growing interest in AI solutions for regulated healthcare sectors.
